🔗 Visit the ClinicalTrials.gov page for NCT01016483
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | MEK and the inhibitors: from bench to bedside. | J Hematol Oncol | 2013 | 1.90 |
| 2 | Current and future systemic treatment options in metastatic pancreatic cancer. | J Gastrointest Oncol | 2014 | 0.95 |
| 3 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. | Oncogene | 2015 | 0.90 |
| 4 | Aberrant signaling pathways in pancreatic cancer: a two compartment view. | Mol Carcinog | 2012 | 0.90 |
| 5 | Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. | Oncologist | 2014 | 0.87 |